Cargando…

Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation

BACKGROUND: Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be translated into clinical practice because of its hematopoiesis-associated side effects while non-erythropoietic asialo-rhuEPO is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kittur, Farooqahmed S., Lin, Yuan, Arthur, Elena, Hung, Chiu-Yueh, Li, P. Andy, Sane, David C., Xie, Jiahua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327940/
https://www.ncbi.nlm.nih.gov/pubmed/30671548
http://dx.doi.org/10.1016/j.bbrep.2019.01.004
_version_ 1783386572795674624
author Kittur, Farooqahmed S.
Lin, Yuan
Arthur, Elena
Hung, Chiu-Yueh
Li, P. Andy
Sane, David C.
Xie, Jiahua
author_facet Kittur, Farooqahmed S.
Lin, Yuan
Arthur, Elena
Hung, Chiu-Yueh
Li, P. Andy
Sane, David C.
Xie, Jiahua
author_sort Kittur, Farooqahmed S.
collection PubMed
description BACKGROUND: Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be translated into clinical practice because of its hematopoiesis-associated side effects while non-erythropoietic asialo-rhuEPO is unavailable in large quantities for clinical studies. This study was designed to investigate the cardiomyocyte protective potential of plant-produced asialo-rhuEPO (asialo-rhuEPO(P)) against staurosporine (STS)-induced injury in HL-1 murine cardiomyocytes and identify cellular pathway(s) responsible for its cardioprotection. METHODS: HL-1 cardiomyocytes were simultaneously treated with STS and asialo-rhuEPO(P). Cellular injury, apoptosis, and cell viabilities were measured by LDH assay, Hoechst staining and trypan blue exclusion method, respectively while western blotting was used to study its effects on apoptosis and autophagy hallmarks. RESULTS: Our results showed that 20 IU/ml asialo-rhuEPO(P) provided 39% protection to cardiomyocytes compared to STS-treated cells, which is 2-fold better than that of mammalian cell-produce rhuEPO (rhuEPO(M)). Asialo-rhuEPO(P) was found to suppress activation of proapoptotic kinase Mst1 (mammalian Sterile-20-like kinase 1) and FOXO3, leading to inhibition of apoptotic pathway and restoration of autophagy as indicated by the reduction of fragmented/condensed nuclei, altered ratios of Bax/Bcl2, p-Bad/Bad, cytosol/mitochondrial cyt c and caspase-3 activation, and the restored levels of autophagy markers Beclin1, p62 and LC3B-II. Additionally, Akt was found to be activated and FOXO3 was phosphorylated on Ser253, suggesting inhibition of FOXO3 transcriptional function. CONCLUSIONS: Asialo-rhuEPO(P)-mediated cardioprotection occurs through activation of PI3K/Akt pathway leading to suppression of Mst1 activation and promoting cardiomyocyte survival. GENERAL SIGNIFICANCE: Asialo-rhuEPO(P) could be used to modulate Mst1 activity elevated under numerous pathological states.
format Online
Article
Text
id pubmed-6327940
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63279402019-01-22 Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation Kittur, Farooqahmed S. Lin, Yuan Arthur, Elena Hung, Chiu-Yueh Li, P. Andy Sane, David C. Xie, Jiahua Biochem Biophys Rep Review Article BACKGROUND: Recombinant human erythropoietin (rhuEPO) and asialoerythropoietin (asialo-rhuEPO) are cardioprotective. However, the protective effects of rhuEPO could not be translated into clinical practice because of its hematopoiesis-associated side effects while non-erythropoietic asialo-rhuEPO is unavailable in large quantities for clinical studies. This study was designed to investigate the cardiomyocyte protective potential of plant-produced asialo-rhuEPO (asialo-rhuEPO(P)) against staurosporine (STS)-induced injury in HL-1 murine cardiomyocytes and identify cellular pathway(s) responsible for its cardioprotection. METHODS: HL-1 cardiomyocytes were simultaneously treated with STS and asialo-rhuEPO(P). Cellular injury, apoptosis, and cell viabilities were measured by LDH assay, Hoechst staining and trypan blue exclusion method, respectively while western blotting was used to study its effects on apoptosis and autophagy hallmarks. RESULTS: Our results showed that 20 IU/ml asialo-rhuEPO(P) provided 39% protection to cardiomyocytes compared to STS-treated cells, which is 2-fold better than that of mammalian cell-produce rhuEPO (rhuEPO(M)). Asialo-rhuEPO(P) was found to suppress activation of proapoptotic kinase Mst1 (mammalian Sterile-20-like kinase 1) and FOXO3, leading to inhibition of apoptotic pathway and restoration of autophagy as indicated by the reduction of fragmented/condensed nuclei, altered ratios of Bax/Bcl2, p-Bad/Bad, cytosol/mitochondrial cyt c and caspase-3 activation, and the restored levels of autophagy markers Beclin1, p62 and LC3B-II. Additionally, Akt was found to be activated and FOXO3 was phosphorylated on Ser253, suggesting inhibition of FOXO3 transcriptional function. CONCLUSIONS: Asialo-rhuEPO(P)-mediated cardioprotection occurs through activation of PI3K/Akt pathway leading to suppression of Mst1 activation and promoting cardiomyocyte survival. GENERAL SIGNIFICANCE: Asialo-rhuEPO(P) could be used to modulate Mst1 activity elevated under numerous pathological states. Elsevier 2019-01-09 /pmc/articles/PMC6327940/ /pubmed/30671548 http://dx.doi.org/10.1016/j.bbrep.2019.01.004 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Kittur, Farooqahmed S.
Lin, Yuan
Arthur, Elena
Hung, Chiu-Yueh
Li, P. Andy
Sane, David C.
Xie, Jiahua
Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
title Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
title_full Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
title_fullStr Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
title_full_unstemmed Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
title_short Recombinant asialoerythropoetin protects HL-1 cardiomyocytes from injury via suppression of Mst1 activation
title_sort recombinant asialoerythropoetin protects hl-1 cardiomyocytes from injury via suppression of mst1 activation
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327940/
https://www.ncbi.nlm.nih.gov/pubmed/30671548
http://dx.doi.org/10.1016/j.bbrep.2019.01.004
work_keys_str_mv AT kitturfarooqahmeds recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation
AT linyuan recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation
AT arthurelena recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation
AT hungchiuyueh recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation
AT lipandy recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation
AT sanedavidc recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation
AT xiejiahua recombinantasialoerythropoetinprotectshl1cardiomyocytesfrominjuryviasuppressionofmst1activation